Emerging retatrutide, a twin -action medication targeting equally GLP-1 and GIP receptors, is creating considerable interest within the healthcare community. Initial clinical studies have shown impressive decreases in physical mass and advancements in metabolic markers for patients with obesity . Experts believe this novel approach has the potentia